Tag Archives: Helicobacter pylori eradication therapy

Helicobacter pylori (Hp) chronic infection is increasing worldwide and is involved in the pathogenesis of chronic gastritis, peptic ulcers, and gastric cancer. Eradication of the bacterium through proton-pump inhibitor (PPI)-based triple therapy (PPI, amoxicillin and either clarithromycin or metronidazole and clarithromycin) or bismuth-based quadruple therapy (bismuth added to the standard twice-daily PPI-based triple therapy) has recently decreased, mainly due to…

Paul Enck
Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.

Helicobacter pylori (Hp) chronic infection is increasing worldwide and is involved in the pathogenesis of chronic gastritis, peptic ulcers, and gastric cancer. Eradication of the bacterium through proton-pump inhibitor (PPI)-based triple therapy (PPI, amoxicillin and either clarithromycin or metronidazole and clarithromycin) or bismuth-based quadruple therapy (bismuth added to the standard twice-daily PPI-based triple therapy) has recently decreased, mainly due to…

Paul Enck
Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.